The effect of calcineurin inhibitors on endothelial function in renal transplant recipients

被引:51
|
作者
Oflaz, H
Turkmen, A
Kazancioglu, R
Kayacan, SM
Bunyak, B
Genchallac, H
Erol, B
Mercanoglu, F
Umman, S
Sever, MS
机构
[1] Istanbul Sch Med, Dept Cardiol, Istanbul, Turkey
[2] Istanbul Sch Med, Dept Radiodiagnost, Istanbul, Turkey
[3] Istanbul Sch Med, Dept Urol, Istanbul, Turkey
[4] Istanbul Sch Med, Dept Internal Med, Div Nephrol, Istanbul, Turkey
关键词
cyclosporine; endothelial function; renal transplantation; tacrolimus;
D O I
10.1034/j.1399-0012.2003.00030.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Endothelial dysfunction is of vital importance, as it may cause ischemia and dysfunction in various organs. Despite, this problem has been well documented in patients with end-stage renal disease (ESRD), there is not enough data considering this issue following renal transplantation. One of the potential causes of endothelial dysfunction in renal transplant recipients may be administration of calcineurin inhibitors. The aim of this study is to evaluate the effects of two different calcineurin inhibitors [cyclosporin A (CsA) and tacrolimus (FK506)] on endothelial function in renal transplant patients. Forty-four renal transplant recipients [22 on FK506 (group I) and 22 on CsA (group II)] were studied. Endothelial functions of the brachial artery were evaluated by using high resolution vascular ultrasound. Endothelium-dependent and -independent vasodilations were assessed by establishing reactive hyperemia and using sublingual nitroglycerine (NTG), respectively. Results are presented as percentage change from baseline values. Significant endothelial dysfunction was noted in renal transplant patients treated with CsA. While endothelium-dependent vasodilation was 12.1+/-5.1% in group I and it was 6.5+/-3.7% in group II (p<0.001). The increase in brachial artery diameter after sublingual NTG was 20.1+/-6.3 and 12.7+/-5.6% in groups I and II, respectively. This indicates that the endothelium-dependent and -independent vasodilation of the patients on FK506 is better preserved than the patients on CsA therapy. Besides, blood flow volume (BFV) increase was 51.2+/-39.4 and 43.9+/-24.3%, in groups I and II, respectively, in reactive hyperemia period (p>0.05). Post-transplant course of renal transplant recipients is complicated by endothelial dysfunction. This problem is more prominent in patients on CsA therapy, which can predispose these patients to more frequent cardiac complications.
引用
收藏
页码:212 / 216
页数:5
相关论文
共 50 条
  • [21] Lipid parameters, doses and blood levels of calcineurin inhibitors in renal transplant recipients
    Ciftci, H. S.
    Ayna, T. K. U.
    Caliskan, Y.
    Turkmen, A.
    Gurtekin, M.
    [J]. THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 544 - 544
  • [22] Rapamycin for treatment of renal insufficiency related to calcineurin inhibitors in liver transplant recipients
    Habib, A
    Bacon, BR
    Befeler, AS
    Ramrakhiani, S
    Ramrakhiani, S
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A92 - A92
  • [23] ASSOCIATION OF SERUM ADIPONECTIN LEVELS WITH ENDOTHELIAL AND PLATELET FUNCTION IN RENAL TRANSPLANT PATIENTS USING CALCINEURIN INHIBITORS
    Sahin, Garip
    Akay, Olga Meltem
    Uslu, Sema
    Bal, Cengiz
    Yalcin, Ahmet Ugur
    Gulbas, Zafer
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 274 - 274
  • [24] Changes in Immunophenotypes After Conversion from Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplant Recipients
    Yildiz, A.
    Cavusoglu, M.
    Adin, S.
    Caliskan, Y.
    Ozkok, A.
    Tasci, H.
    Deniz, G.
    Sariyar, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [25] Calcineurin inhibitors’ impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain
    Rita Nogueiras-Álvarez
    Víctor Manuel Mora-Cuesta
    José Manuel Cifrián-Martínez
    María Ángeles de Cos-Cossío
    María del Mar García-Sáiz
    [J]. Scientific Reports, 12
  • [26] Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients
    Tsai, Kai-Fan
    Li, Lung-Chih
    Hsu, Chien-Ning
    Lin, Chih-Che
    Lin, Yu-Hung
    Cheng, Yu-Fan
    Wang, Chih-Chi
    Chen, Chao-Long
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (03): : 326 - 334
  • [27] Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function
    Masetti, M.
    Montalti, R.
    Rompianesi, G.
    Codeluppi, M.
    Gerring, R.
    Romano, A.
    Begliomini, B.
    Di Benedetto, F.
    Gerunda, G. E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (10) : 2252 - 2262
  • [28] Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in De Novo Liver Transplant Recipients Preserves Renal Function
    Montalti, Roberto
    Rompianesi, Gianluca
    Di Benedetto, Fabrizio
    Codeluppi, Mauro
    Cautero, Nicola
    Guerrini, Gian Piero
    Smerieri, Nazareno
    Serra, Valentina
    Iemmolo, Rosa Maria
    Marino, Maria
    De Pietri, Lesley
    Gerunda, Giorgio Enrico
    [J]. LIVER TRANSPLANTATION, 2010, 16 (06) : S134 - S134
  • [29] Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain
    Nogueiras-Alvarez, Rita
    Manuel Mora-Cuesta, Victor
    Manuel Cifrian-Martinez, Jose
    Angeles de Cos-Cossio, Maria
    del Mar Garcia-Saiz, Maria
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [30] Daclizumab permits delayed introduction of calcineurin inhibitors in renal transplant recipients at risk for delayed graft function.
    Golconda, MS
    Rayhill, SC
    Hunsicker, LG
    [J]. TRANSPLANTATION, 2000, 69 (08) : S158 - S158